An Innovative, Paradigm-Shifting Lifestyle Intervention to Reduce Glucose Excursions With the Use of Continuous Glucose Monitoring to Educate, Motivate, and Activate Adults With Newly Diagnosed Type 2 Diabetes: Pilot Feasibility Study

• Published in: JMIR diabetes Vol. 7; no. 1; p. e34465
• Main Authors: Oser, Tamara K, Cucuzzella, Mark, Stasinopoulos, Marilyn, Moncrief, Matthew, McCall, Anthony, Cox, Daniel J
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 23-02-2022
• Subjects: Automation; Carbohydrates; Cardiovascular disease; Diabetes; Empowerment; Exercise; Feasibility studies; Feedback; Food; Glucose monitoring; Hemoglobin; Lifestyles; Medical diagnosis; Metabolism; Original Paper; Physical fitness; Questionnaires; Sensors; Text messaging; United States > US; distress; treatment; pilot study; motivation; monitoring; lifestyle; glycemic excursion minimization; type 2 diabetes; initial treatment; continuous glucose monitoring; intervention; diabetes; diabetes distress
• ISSN: 2371-4379; 2371-4379
• DOI: 10.2196/34465

Type 2 diabetes (T2D) is a growing epidemic in the United States, and metabolic control has not been improved over the last 10 years. Glycemic excursion minimization (GEM) is an alternative lifestyle treatment option focused on reducing postnutrient glucose excursions rather than reducing weight. GEM has been proven to be superior to routine care when delivered face to face, and equivalent or superior to conventional weight loss therapy, but it has not been evaluated among patients newly diagnosed with T2D or in a self-administered format.
This pilot study evaluated the feasibility of a self-administered version of GEM, augmented with continuous glucose monitoring (CGM), to improve metabolic control (hemoglobin A
[HbA
]) while diminishing or delaying the need for diabetes medications in adults recently diagnosed with T2D. These primary objectives were hypothesized to be achieved by reducing carbohydrate intake and increasing physical activity to diminish CGM glucose excursions, leading to the secondary benefits of an increase in diabetes empowerment and reduced diabetes distress, depressive symptoms, and BMI.
GEM was self-administered by 17 adults recently diagnosed with T2D (mean age 52 years, SD 11.6 years; mean T2D duration 3.9 months, SD 2.5 months; mean HbA
levels 8.0%, SD 1.6%; 40% female; 33.3% non-White), with the aid of a 4-chapter pocket guide and diary, automated motivational text messaging, and feedback from an activity monitor, along with CGM and supplies for the 6-week intervention and the 3-month follow-up. Treatment was initiated with one telephone call reviewing the use of the technology and 3 days later with a second call reviewing the use of the GEM pocket guide and intervention.
At 3-month follow-up, 67% of the participants' diabetes was in remission (HbA
levels <6.5%), and only one participant started taking diabetes medication. Participants demonstrated a significant reduction in HbA
levels (-1.8%; P<.001). Participants also experienced significant reductions in high-glycemic-load carbohydrates routinely consumed, CGM readings that were >140 mg/dL, diabetes distress, depressive symptoms, and BMI. Participants felt that use of the CGM was the most significant single element of the intervention.
GEM augmented with CGM feedback may be an effective initial intervention for adults newly diagnosed with T2D. A self-administered version of GEM may provide primary care physicians and patients with a new tool to help people recently diagnosed with T2D achieve remission independent of medication and without weight loss as the primary focus. Future research is needed with a larger and more diverse sample.